Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy-Reference-Cited by-同舟云学术

Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy

Published:2022-12-08 Issue:6 Volume:12 Page:7175-7181
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Medicine

Author:

Laloi Louise¹,Billotey Natacha Chaumard¹,Dumas Pierre‐Yves²^ORCID,Paul Franciane³,Villate Alban⁴,Simand Célestine⁵,Fornecker Luc⁵,Puisset Florent⁶^ORCID,Bertoli Sarah⁷,Simonet Marion Boissard⁸,Laribi Kamel⁹^ORCID,Houyou Dyhia¹⁰,Santagostino Alberto¹¹,Michel Claire¹²^ORCID,Guepin Gabrielle Roth¹²,Guerineau Elodie¹³,Tabrizi Reza¹⁴,Hunault Mathilde¹⁵,Giltat Aurélien¹⁵,Kaphan Eléonore¹⁶,Bulabois Claude¹⁶,Cartet Elodie¹⁷,Rocher Clément¹⁸,Lachenal Florence¹⁸,Morisset Stéphane¹⁹,Récher Christian⁷^ORCID,Pigneux Arnaud²,Belhabri Amine²⁰^ORCID,Michallet Mauricette²⁰,Michallet Anne‐Sophie²⁰^ORCID

Affiliation:

1. Department of Pharmacy Centre Léon Bérard Lyon France

2. Department of Hematology University Hospital of Bordeaux Bordeaux France

3. Department of Hematology University Hospital of Montpellier Montpellier France

4. Department of Hematology University Hospital of Tours Tours France

5. Department of Hematology University Hospital of Strasbourg Strasbourg France

6. Department of Pharmacy Institut Universitaire du Cancer Oncopole Toulouse France

7. Department of Hematology Institut Universitaire du Cancer Oncopole Toulouse France

8. Department of Hematology University Hospital of Besançon Besançon France

9. Department of Hematology Hospital of Le Mans Le Mans France

10. Department of Clinical Research Hospital of Troyes Troyes France

11. Department of Hematology Hospital of Troyes Troyes France

12. Department of Hematology University Hospital of Nancy Nancy France

13. Department of Clinical Research Hospital of Mont de Marsan Mont de Marsan France

14. Department of Hematology Hospital of Mont de Marsan Mont de Marsan France

15. Department of Hematology University Hospital of Angers Angers France

16. Department of Hematology University Hospital of Grenoble Grenoble France

17. Department of Pharmacy Hospital of Bourgoin‐Jallieu Bourgoin‐Jallieu France

18. Department of Hematology Hospital of Bourgoin‐Jallieu Bourgoin‐Jallieu France

19. Independent Biostatistician Pérouges France

20. Department of Hematology and Medical Oncology Centre Léon Bérard Lyon France

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.5459

Reference20 articles.

1. Le Guyader‐PeyrouS DefossezG DantonyE et al.Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Volume 2: Hémopathies malignes. Étude à partir des registres des cancers du réseau Francim.2019. p.169. Accessed 6 September 2022.https://www.santepubliquefrance.fr/docs/estimations‐nationales‐de‐l‐incidence‐et‐de‐la‐mortalite‐par‐cancer‐en‐france‐metropolitaine‐entre‐1990‐et‐2018‐volume‐2‐hemopathies‐malignes

2. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

3. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial

4. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

5. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold?;Annals of Hematology;2024-08-16

2. Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML;Leukemia Research;2024-08

3. Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece;Journal of Clinical Medicine;2024-01-19

4. Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies;Cancers;2023-09-18